Novartis in the news

Swiss stocks rose modestly led by UBS and pharma firms amid solid US job data and regulatory clarity for banks, while Tesla shares fluctuated due to a public feud between Musk and Trump.

The US FDA appointed Prasad as vaccine official amid pressure on Roche and Novartis.

Novartis shares rose on positive cancer drug trial results amid a broadly cautious market affected by US tariff hikes and geopolitical tensions.

Trump featured Novartis CEO in a promotional video highlighting US investments amid potential US drug tariffs and contrasting Roche's absence.

Novartis CEO and Basel's government president unveiled a 'Basel' bench at the Rhine, donated by Novartis as part of its ESC sponsorship.

A Novartis manager sold shares valued at 13.1 million Swiss francs, disclosed to the Swiss stock exchange.

Novartis reported positive Phase-III results for Pluvicto in treating PSMA-positive metastatic hormone-sensitive prostate cancer, supporting earlier use and regulatory submission plans.

Novartis shares rose on positive cancer therapy data amid a volatile market influenced by US tariff hikes, pharma acquisitions, and economic uncertainties.

Novartis raised its 2024 revenue and profit outlook after a strong Q1 driven by key drugs and plans US manufacturing expansion amid tariff concerns.

Novartis announced new Phase-2 study data showing the effects of Kisqali combined with endocrine therapy in breast cancer patients.

Novartis reported positive Phase III study results for Pluvicto improving progression-free survival in prostate cancer, supporting earlier use.

Novartis CEO is optimistic despite US tariffs, raising sales forecasts while urging Europe to increase drug prices to stay competitive amid upcoming US generic competition and tariff challenges.

Novartis is acquiring Regulus Therapeutics, which develops RNA therapies for a common genetic kidney disease, for up to $1.7 billion.

Novartis supports the Eurovision Song Contest financially despite facing US pressure over its diversity policies.

Novartis and Sanofi are pushing for increased drug prices in Europe, as discussed in an open letter.

Novartis plans a $23 billion US investment to expand research and manufacturing, featured in a Trump video promoting tariffs' economic impact.

Trump used footage of Novartis CEO in a campaign video without consent, highlighting Novartis' $23 billion US investment amid tariff concerns.

Novartis is acquiring US biotech Regulus Therapeutics for up to $1.7 billion to enhance its kidney disease pipeline with RNA-based therapies.

Novartis posted strong Q1 2025 results with double-digit profit growth, raised its full-year outlook for the ninth quarter in a row, and remains confident despite upcoming generic competition.

Novartis shares rose amid strong Q1 2025 results showing revenue growth and higher earnings per share, with dividends and future earnings forecasts positive.